AnaptysBio (NASDAQ:ANAB) Price Target Cut to $36.00 by Analysts at Guggenheim

AnaptysBio (NASDAQ:ANAB) had its target price decreased by Guggenheim from $90.00 to $36.00 in a research report released on Thursday morning,Benzinga reports. Guggenheim currently has a buy rating on the biotechnology company’s stock.

A number of other analysts have also recently commented on ANAB. BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. decreased their price objective on shares of AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Wedbush reissued an “outperform” rating and set a $40.00 target price (down previously from $42.00) on shares of AnaptysBio in a report on Wednesday. UBS Group boosted their price target on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, HC Wainwright downgraded shares of AnaptysBio from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $52.00 to $19.00 in a research report on Wednesday. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.09.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $15.59 on Thursday. The firm has a market capitalization of $474.40 million, a P/E ratio of -2.56 and a beta of -0.11. The business’s 50-day moving average is $25.56 and its 200 day moving average is $29.43. AnaptysBio has a 1 year low of $14.20 and a 1 year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. On average, analysts expect that AnaptysBio will post -6.02 EPS for the current year.

Insider Activity

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. The trade was a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at $189,333.04. This represents a 72.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,440 shares of company stock worth $892,936 over the last quarter. 33.70% of the stock is currently owned by corporate insiders.

Institutional Trading of AnaptysBio

Institutional investors have recently made changes to their positions in the company. Values First Advisors Inc. purchased a new position in shares of AnaptysBio during the 3rd quarter worth $49,000. nVerses Capital LLC lifted its position in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 1,400 shares during the last quarter. Headlands Technologies LLC boosted its stake in AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after buying an additional 2,900 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of AnaptysBio by 81.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 2,600 shares during the last quarter. Finally, Point72 DIFC Ltd raised its stake in shares of AnaptysBio by 680.5% in the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 5,342 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.